Delivery Order SPE2DB24D3013-SPE2DB25FFQQS
- Not listed
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,360.72 for Zepbound 7.5 mg/0.5 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply services under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $17,506.81 on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectable medication, with final completion scheduled for August 21, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,306.78 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This competitive award, with a completion date of July 30, 2025, represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply arrangements with the federal government. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where the company operates as a major...
- The Defense Logistics Agency awarded a delivery order valued at $6,578.39 to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 ml pen injections on September 15, 2025, with completion scheduled for September 16, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.999 billion through December 2026. The product will be performed...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 5 mg/0.5 mL pens valued at $3,050.32 with a completion date of August 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, executed under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,594.12 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pens on July 14, 2025, with completion scheduled for July 15, 2025. This non-competitive delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract represents a routine pharmaceutical supply transaction in support of...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $22,877.40 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX and valued at $999,999,999. The delivery location is...
- The Defense Logistics Agency awarded a delivery order valued at $13,836.67 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQQSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,595.79 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pens on September 16, 2025, with completion scheduled for September 17, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government's military and veteran healthcare systems. As the prime contractor under the DLA Troop Support Medical IDC, the company supplies a comprehensive portfolio of pharmaceutical products across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. Zepbound, a brand-name diabetes medication, reflects the company's capacity to deliver specialty pharmaceuticals essential to federal medical supply chains serving military personnel and beneficiaries worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 9/16/25 |